Multiple Myeloma
Conference Coverage
Melflufen-dexamethasone active in patients with relapsed/refractory myeloma and EMD
BOSTON – Melflufen plus dexamethasone produced similar response rates in patients with and without extramedullary disease.
From the Journals
VRD pretransplant induction deepens responses in myeloma
The researchers wrote that the unique dosing of the three-drug induction regimen may be considered a new standard of care.
From the Journals
Progressive myeloma after induction? Go straight to transplant
The study did not find a survival advantage for patients who had salvage therapy to deepen their responses before moving on to transplant.
From the Journals
Combo produces responses in triple-class refractory myeloma
Selinexor plus low-dose dexamethasone produced a response rate of 26% in patients who were refractory to at least one proteasome inhibitor, one...
From the Journals
Cardiovascular complications most common with carfilzomib in relapsed myeloma
For patients taking carfilzomib-based therapy, the most common complications were heart failure, followed by grade 3 or 4 hypertension.
From the Journals
TP53 double hit predicts aggressive myeloma
Researchers said the findings point to the usefulness of clonal competition assays to reveal the impact of genomic lesions in tumors and better...
Opinion
Potential improvements in convenience, tolerability of hematologic treatment
Dr. Alan P. Lyss dissects the practice changing elements of the COLUMBA trial in multiple myeloma and the ASCEND trial in CLL.
Conference Coverage
SC daratumumab deemed feasible for every multiple myeloma patient
CHICAGO – In the COLUMBA trial, subcutaneous daratumumab proved noninferior to intravenous daratumumab in overall response rate and maximum trough...
From the Journals
Recombinant vaccine cut herpes zoster rate in immunocompromised patients
In a randomized clinical trial of 1,846 adults who had undergone autologous HSCT, herpes zoster cases were seen in 49 and 136 individuals in the...
Latest News
FDA approves Xpovio for relapsed/refractory multiple myeloma
The oral therapy was approved for patients who have received at least four prior therapies and whose disease is resistant to several other forms...
News
Daratumumab wins new indication for newly diagnosed myeloma patients
Daratumumab plus lenalidomide and dexamethasone (DRd) is now approved for newly diagnosed myeloma patients who are ineligible for autologous stem...